Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

ABSTRACT: This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

DISEASE(S): Renal Cell Carcinoma (rcc),Colorectal Cancer (crc),Lung Cancer,Nsclc,Gastric Cancer,Carcinoma, Renal Cell,Mesothelioma,Bladder Cancer,Head And Neck Cancer,Metastatic Cancer,Uc (urothelial Cancer),Solid Tumors

PROVIDER: 2225246 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Immune checkpoint inhibitor-induced colitis

Project description:Immune checkpoint inhibitor-induced colitis

| PRJNA857579 | ENA

Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

Project description:Immune checkpoint inhibitors (ICIs) are improving cancer treatments strikingly. The raising use leads to the augmented occurrence of immune related events. Myocarditis is a rare, but severe form of these adverse events. Nine patients with proven ICI induced myocarditis were subjected to myocardial biopsy. The tissue was used for RNA-seq analyses.

2020-11-01 | E-MTAB-8867 | biostudies-arrayexpress

Restoring PD-1 immune checkpoint inhibitor response following IFNγ-driven adaptive resistance

Project description:Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by targeting molecules on immune cells that can inhibit the immune system's ability to attack cancer cells. One such checkpoint molecule is PD-1, which is found on the surface of T cells (a type of immune cell) and helps to prevent them from attacking healthy cells. When PD-1 binds to its ligand (a molecule on the surface of some cells), it sends a signal to the T cell to \\"turn off\\" and not attack the cell. This mechanism is important in preventing the immune system from attacking healthy cells, but it can also be exploited by cancer cells to avoid detection and destruction by the immune system. In this study YUMM2.1 mouse tumour cells were implanted subcutaneously. The effect of IFN-γ-pre-treatment, PARP14 inhibition and PD-1 antibody treatment are reported by RNA-seq.

2023-08-22 | E-MTAB-12872 | biostudies-arrayexpress

Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis

Project description:We conducted single-cell and T-cell receptor transcriptomic sequencing on the bronchoalveolar lavage fluid from five patients with grade ≥2 immune checkpoint inhibitor-related pneumonitis. Our analyses revealed a prominent enrichment of T cells in the bronchoalveolar lavage fluid of patients with immune checkpoint inhibitor-related pneumonitis.

2024-09-13 | GSE277136 | GEO

Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis

Project description:Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis

| PRJNA1494521 | ENA

Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis

Project description:Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis

| PRJNA1449525 | ENA

IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

Project description:IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

| PRJNA1266108 | ENA

Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis [CosMx]

Project description:Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis [CosMx]

| PRJNA1447584 | ENA

Immune Re-sensitization in Checkpoint Inhibitor Refractory and Relapsed Cancers with Plinabulin, Radiation and Immune Checkpoint Blockade

Project description:Immune Re-sensitization in Checkpoint Inhibitor Refractory and Relapsed Cancers with Plinabulin, Radiation and Immune Checkpoint Blockade

| PRJNA1078290 | ENA

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRASG12C-mutant NSCLC for Immune Checkpoint Blockade

Project description:To address RAS pathway hyperactivation and targeted therapy resistance in KRASG12C-mutant NSCLC, we evaluated the potential of the RAS(ON) G12C-selective covalent inhibitor elironrasib and the RAS(ON) multi-selective inhibitor daraxonrasib combination to maximize RAS pathway suppression and forestall pathway reactivation in a series of preclinical models. We demonstrate that the RAS(ON) inhibitor doublet induces profound and sustained tumor regressions and overcomes the increased RAS pathway oncogenic flux that underlies resistance to inactive state–selective KRASG12C inhibitors in NSCLC. Additionally, in immune-competent preclinical models, the RAS(ON) inhibitor doublet enhances tumor immune recognition by boosting antigen presentation and remodeling the suppressive tumor microenvironment, thus promoting immune-dependent complete regressions and sensitization of an immuno-refractory model to checkpoint blockade. Collectively these findings provide a preclinical rationale for the evaluation of a targeted RAS(ON) inhibitor doublet therapy regimen in combination with immune checkpoint blockade in patients with KRASG12C-mutant NSCLC.

2025-12-29 | GSE315010 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data